Aquestive Therapeutics will release its fourth quarter and full-year 2025 financial results on March 4, 2026, followed by a live conference call with investors and analysts on March 5 at 8:00 a.m. ET. The earnings announcement will provide insight into the company's financial performance and operational developments during the period.
The pharmaceutical company continues advancing its clinical pipeline, including Anaphylm™ (dibutepinephrine), a sublingual film formulation designed for rapid treatment of severe allergic reactions. The company has also been developing AQST-108, a topical gel candidate for dermatological applications. Recent clinical evaluations of Anaphylm™ have demonstrated epinephrine plasma concentration levels consistent with therapeutic objectives for anaphylaxis management.
Investors and market participants are encouraged to dial into the March 5 conference call to hear management's discussion of financial results, business performance, and strategic initiatives. Additional details regarding access to the earnings release and webcast will be provided in due course.